Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone plus prednisone with or without abemaciclib in metastatic castration-resistant prostate cancer
2016-004276-21Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) comparing Abemaciclib + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Primary endpoint: Safety and tolerability (Part 1). Started Oct 2018; status: active.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-004276-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004276-21.